For the Inventor, By the Inventor

Enter assignee name

Askat Inc.

Calculating rank

USPTO Granted Patents = 15

% Expired Patents = 6.7

CIPO Patents = 2

EPO Patents = 10

Forward Citations = 26

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Takako Okumura (11 out of 13 patents)

Shinichi Koizumi (7 out of 14 patents)

Yukinori Take (5 out of 7 patents)

4. Kazuhiko Nonomura (4 out of 7 patents)

5. Yoshiyuki Okumura (4 out of 19 patents)

6. Yukari Inami (3 out of 3 patents)

7. Naoko Ohtani (2 out of 5 patents)

8. Fumitaka Kamachi (2 out of 2 patents)

9. Tze Mun Loo (2 out of 4 patents)

10. Tracy Walker (2 out of 2 patents)

11. Mark Manfredi (1 out of 1 patent)

12. Jeffrey Ecsedy (1 out of 1 patent)

13. Atsushi Nagahisa (1 out of 1 patent)

14. Masaki Sudo (1 out of 8 patents)

15. Alfredo C Castro (1 out of 114 patents)

15 patents: Sort by Forward Citations

1. 12617776 - Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol (2026-05-05),

2. 12295962 - Polymorphic compounds and uses thereof (2025-05-13),

3. 11964963 - Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol (2024-04-23),

4. 11840530 - Selective EP4 receptor antagonistic substance for treatment of cancer (2023-12-12),

5. 11555023 - Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids (2023-01-17),

6. 10973834 - EP4 inhibitors and use thereof (2021-04-13),

7. 10947235 - Selective EP4 receptor antagonistic substance for treatment of cancer (2021-03-16),

8. 10786490 - Use of EP4 receptor antagonists in the treatment of cartilage disease (2020-09-29),

9. 10611761 - Selective EP4 receptor antagonistic substance for treatment of cancer (2020-04-07),

10. 10583129 - Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer (2020-03-10),

11. 10391086 - Use of EP4 receptor antagonists in the treatment of cartilage disease (2019-08-27),

12. 10342785 - Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer (2019-07-09),

13. 9688674 - Selective EP4 receptor antagonistic substance for treatment of cancer (2017-06-27),

14. 9561210 - Therapeutic agent for ocular disease (2017-02-07),

15. 9447066 - Salts and crystal forms (2016-09-20),

Company Overview

Askat Inc. is a technology-focused company based in Nagoya, Japan, specializing in advanced engineering solutions and innovative product development. The organization is dedicated to enhancing various industries through its expertise in automation, robotics, and precision manufacturing. Askat Inc. leverages cutting-edge research to create systems that improve efficiency and performance, positioning itself as a key player in the evolving landscape of technology and engineering solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

15 Patents

#62 in Nagoya

#3,447 in Japan

#39,959 in the World

Askat Inc.

Forward Citations = 26

21 inventors:

Takako Okumura (11 out of 13 patents)

Shinichi Koizumi (7 out of 14 patents)

Yukinori Take (5 out of 7 patents)

4. Kazuhiko Nonomura (4 out of 7 patents)

5. Yoshiyuki Okumura (4 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Askat Inc.. Retrieved from https://idiyas.com/company/askat

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…